Mixed amphetamine salts

Clinical contraindication: None listed; No clinical contraindication identified.
Best available evidence: Mechanism only; Also: standard practice.
Half-life: 10 h; Approximate, in adults. Detail in 01.

Named in state rules?

CONot named

ORNot named

NMPending

Cite asPsilodex: mixed-amphetamine-salts · v2026.10.02

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

01 Interaction with psilocybin

Th · Pr

Sympathomimetic stacking: additive BP, heart rate and anxiety rise; tachycardia, hypertension and seizure warnings.

Human data with psilocybin: None known: no published human data with psilocybin
Half-life: d-amphetamine 10 h; l-amphetamine 13 h (adults) (FDA label, checked 2026-09-30)

Evidence types on this record

ThMechanism only (theoretical)

PrStandard practice; no psilocybin-specific data

2 listed · counted on reports

Raises blood pressure or heart rate: Raises blood pressure or heart rate. Psilocybin raises both for several hours, so the effects can add. Sources [1]
Lowers seizure threshold or carries seizure risk: Makes a seizure more likely, or has been linked to seizures. Sources [1]

Plain-language summary · official text governs

CO4 CCR 755-1

Not named

No provision names this medication or its class.

Colorado · checked 2026-09-30

OROAR 333-333

Not named

No provision names this medication or its class.

Oregon · checked 2026-09-30

NM7.35.3 NMAC (proposed)

Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-09-30

None linked

No condition named in state rules is linked to this medication.